Voretigene Neparvovec-rzyl (Luxturna)

Covered only for patients ≥1 year with genetically confirmed biallelic RPE65 mutation-associated retinal dystrophy who have viable retinal cells and have not previously received Luxturna (no off‑label/compendial uses covered). Requires documentation of biallelic RPE65 testing, physician confirmation of viable retinal cells and age, and adherence to FDA dosing/administration (1.5×10^11 vg per eye in 0.3 mL subretinally, each eye on separate days ≥6 days apart) with a lifetime limit of two doses (one per eye).

"Luxturna is indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy."

Sign up to see full coverage criteria, indications, and limitations.